Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

Figure 1

Mechanisms of resistance to EGFR TKIs and multiple strategies to overcome resistance in EGFR mutant lung cancer. EGFR signals through the RAS/RAF/MEK/ERK and PI3K/AKT pathways to promote cellular proliferation and survival. Crosstalk of other receptor tyrosine kinase confers resistance to EGFR TKIs by activation of both MAPK and AKT signaling. The FAS/NFκB signaling arm downstream of FAS death receptor also contributes to resistance to EGFR TKIs. Available targeted agents that act against pathways that drive EGFR TKI resistance and that may overcome resistance to EGFR TKIs in appropriately selected lung cancer patients are shown.